Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Rhea-AI Summary

Clene Inc. (NASDAQ: CLNN) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. Rob Etherington, President and CEO of Clene, will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Those interested in scheduling meetings can contact John Perez at jperez@dboralcapital.com.

News Market Reaction – CLNN

-10.53%

-10.53% Session move

In the trading session that priced this news, CLNN declined 10.53%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Salt Lake City, Utah--(Newsfile Corp. - May 7, 2025) - Clene Inc. (NASDAQ: CLNN), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.

Rob Etherington, President and Chief Executive Officer, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET).

To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.

About Clene Inc.
Clene Inc., (NASDAQ: CLNN) (along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

About D. Boral Capital

D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, Middle East, and Latin America.

D. Boral Capital is a leader on Wall Street, having aggregated over $25 billion in capital across approximately 350 transactions through various product types.

For further information:
Clene Inc.
Morgan Brown
Chief Financial Officer
801-201-9626
morgan@clene.com
https://clene.com

Source Clene Inc.

FAQ

When and where is Clene Inc. (CLNN) participating in the D. Boral Capital Conference?

Clene Inc. (CLNN) will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City.

Who will represent Clene Inc. (CLNN) at the D. Boral Capital Conference?

Rob Etherington, President and Chief Executive Officer of Clene Inc., will represent the company at the conference.

What is the schedule for one-on-one meetings with Clene (CLNN) management at the conference?

One-on-one meetings will be held on May 14th from 9:00 A.M. to 3:00 P.M. (ET).

How can investors schedule a meeting with Clene (CLNN) management at the D. Boral Conference?

Interested parties should contact John Perez at jperez@dboralcapital.com to register for one-on-one meetings.